{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:12:46Z","timestamp":1788336766791,"version":"build-2803163510"},"reference-count":47,"publisher":"American Association for Cancer Research (AACR)","issue":"17","funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA274507"],"award-info":[{"award-number":["U54CA274507"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA232382"],"award-info":[{"award-number":["U01CA232382"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA193489"],"award-info":[{"award-number":["U54CA193489"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>A population of cells within a tumor can be described as antifragile (the opposite of fragile) if they derive a benefit from fluctuations or perturbations in environmental conditions induced by treatment. Treatment fluctuations could either promote (antifragile tumor) or inhibit (fragile tumor) the evolution of treatment resistance to targeted therapies. In this study, we showed that analysis of the convexity of dose\u2013response curves provided a direct prediction of response to prescribed fluctuations in treatment. Convexity predicted that continuous treatment protocols (i.e., zero prescribed fluctuations in treatment) would outperform uneven protocols when dose response is convex. This theory was applied to predict in vivo response to targeted therapy, and the predictions were validated by experimentally testing high\/low intermittent dosing (uneven dosing) and continuous dosing (even dosing) schedules. Convexity (and its inverse, concavity) explained 2 phenomena: Dose response is a convex (fragile) function, but the resistance onset rate is a concave (antifragile) function. Thus, design and validation of alternative treatment schedules maximized response while maintaining prolonged sensitivity to treatment. Together, these analyses provide supporting evidence that fluctuations alter the evolutionary trajectory of tumors in response to targeted therapy, even without altering the cumulative dose. By using this insight to design alternative treatment protocols to limit the evolution of resistance by careful analysis of the dose\u2013response curvature, the study supports the potential of \u201cevolutionary antifragile therapy\u201d as a subtype in the broad class of evolution-based treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>The mathematical method using dose response curvature to determine appropriate treatment dosing that limits the evolution of resistance could facilitate designing dose schedules that optimize tumor response.<\/jats:p>\n                    <jats:p>See related commentary by Pomeroy and Palmer, p. 4195<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-25-4262","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T15:01:47Z","timestamp":1779462107000},"page":"4434-4445","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evolutionary Antifragile Therapy Is a Treatment Strategy to Suppress Drug Resistance by Exploiting Dose\u2013Response Convexity"],"prefix":"10.1158","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9579-4664","authenticated-orcid":false,"given":"Jeffrey","family":"West","sequence":"first","affiliation":[{"name":"1Integrated Mathematical Oncology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0454-7583","authenticated-orcid":false,"given":"Bina","family":"Desai","sequence":"additional","affiliation":[{"name":"2Department of Metabolism and Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4484-8823","authenticated-orcid":false,"given":"Maximilian A.R.","family":"Strobl","sequence":"additional","affiliation":[{"name":"3I-X Centre for AI in Science, Imperial College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9831-6676","authenticated-orcid":false,"given":"Jill","family":"Gallaher","sequence":"additional","affiliation":[{"name":"1Integrated Mathematical Oncology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0143-9587","authenticated-orcid":false,"given":"Mark","family":"Robertson-Tessi","sequence":"additional","affiliation":[{"name":"1Integrated Mathematical Oncology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0087-9575","authenticated-orcid":false,"given":"Andriy","family":"Marusyk","sequence":"additional","affiliation":[{"name":"2Department of Metabolism and Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2536-4383","authenticated-orcid":false,"given":"Alexander R.A.","family":"Anderson","sequence":"additional","affiliation":[{"name":"1Integrated Mathematical Oncology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"2026090203152147200_bib1","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s43018-023-00515-0","article-title":"ALK-positive lung cancer: a moving target","volume":"4","author":"Schneider","year":"2023","journal-title":"Nat Cancer"},{"key":"2026090203152147200_bib2","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.ejca.2010.04.002","article-title":"The biology and treatment of EML4-ALK non-small cell lung cancer","volume":"46","author":"Sasaki","year":"2010","journal-title":"Eur J Cancer"},{"key":"2026090203152147200_bib3","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1038\/s41467-020-16212-w","article-title":"Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures","volume":"11","author":"Vander Velde","year":"2020","journal-title":"Nat Commun"},{"key":"2026090203152147200_bib4","first-page":"12","article-title":"FDA\u2019s Brian Booth: \u2018we need to reconsider our approach to dose selection","volume":"48","author":"Tracey","year":"2022","journal-title":"Cancer Lett"},{"key":"2026090203152147200_bib5","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.annonc.2023.08.008","article-title":"Treatment of evolving cancers will require dynamic decision support","volume":"34","author":"Strobl","year":"2023","journal-title":"Ann Oncol"},{"key":"2026090203152147200_bib6","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1158\/0008-5472.CAN-25-0750","article-title":"Mathematical oncology: how modeling is transforming clinical decision-making","volume":"85","author":"Scibilia","year":"2025","journal-title":"Cancer Res"},{"key":"2026090203152147200_bib7","volume-title":"Antifragile: things that gain from disorder","author":"Taleb","year":"2012"},{"key":"2026090203152147200_bib8","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1080\/14697688.2013.800219","article-title":"Mathematical definition, mapping, and detection of (anti) fragility","volume":"13","author":"Taleb","year":"2013","journal-title":"Quantitative Finance"},{"key":"2026090203152147200_bib9","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/nrg1471","article-title":"Biological robustness","volume":"5","author":"Kitano","year":"2004","journal-title":"Nat Rev Genet"},{"key":"2026090203152147200_bib10","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.tree.2020.04.009","article-title":"The importance of genetic redundancy in evolution","volume":"35","author":"L\u00e1ruson","year":"2020","journal-title":"Trends Ecol Evol"},{"key":"2026090203152147200_bib11","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1558-5646.1992.tb02048.x","article-title":"Maintenance of polygenic variation in spatially structured populations: roles for local mating and genetic redundancy","volume":"46","author":"Goldstein","year":"1992","journal-title":"Evolution"},{"key":"2026090203152147200_bib12","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1158\/0008-5472.CAN-08-3658","article-title":"Adaptive therapy","volume":"69","author":"Gatenby","year":"2009","journal-title":"Cancer Res"},{"key":"2026090203152147200_bib13","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3390\/genes2040998","article-title":"Antifragility and tinkering in biology (and in business) flexibility provides an efficient epigenetic way to manage risk","volume":"2","author":"Danchin","year":"2011","journal-title":"Genes"},{"key":"2026090203152147200_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s44260-024-00014-y","article-title":"Antifragility in complex dynamical systems","volume":"1","author":"Axenie","year":"2024","journal-title":"NPJ Complexity"},{"key":"2026090203152147200_bib15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.semcancer.2015.09.002","article-title":"Metronomic reloaded: theoretical models bringing chemotherapy into the era of precision medicine","volume":"35","author":"Benzekry","year":"2015","journal-title":"Semin Cancer Biol"},{"key":"2026090203152147200_bib16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.canlet.2017.03.021","article-title":"Application of mathematical models to metronomic chemotherapy: what can be inferred from minimal parameterized models?","volume":"401","author":"Ledzewicz","year":"2017","journal-title":"Cancer Lett"},{"key":"2026090203152147200_bib17","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.3390\/jcm9051314","article-title":"Optimal control theory for personalized therapeutic regimens in oncology: background, history, challenges, and opportunities","volume":"9","author":"Jarrett","year":"2020","journal-title":"J Clin Med"},{"key":"2026090203152147200_bib18","first-page":"3","article-title":"Experimental evaluation of potential anticancer agents XIII, on the criteria and kinetics associated with \u201ccurability\u201d of experimental leukemia","volume":"35","author":"Skipper","year":"1964","journal-title":"Cancer Chemother Rep"},{"key":"2026090203152147200_bib19","first-page":"1544","article-title":"The effects of chemotherapy on the kinetics of leukemic cell behavior","volume":"25","author":"Skipper","year":"1965","journal-title":"Cancer Res"},{"key":"2026090203152147200_bib20","first-page":"1","article-title":"Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Early Breast Cancer Trialists\u2019 Collaborative Group","volume":"339","year":"1992","journal-title":"Lancet"},{"key":"2026090203152147200_bib21","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1200\/JCO.2001.19.4.1195","article-title":"Redefining the target: chemotherapeutics as antiangiogenics","volume":"19","author":"Miller","year":"2001","journal-title":"J Clin Oncol"},{"key":"2026090203152147200_bib22","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1369","article-title":"The anti-angiogenic basis of metronomic chemotherapy","volume":"4","author":"Kerbel","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"2026090203152147200_bib23","doi-asserted-by":"crossref","first-page":"16ra7","DOI":"10.1126\/scitranslmed.3000389","article-title":"Resiliency and vulnerability in the HER2-HER3 tumorigenic driver","volume":"2","author":"Amin","year":"2010","journal-title":"Sci Transl Med"},{"key":"2026090203152147200_bib24","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/s43018-021-00215-7","article-title":"Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4\/6 therapy","volume":"2","author":"Griffiths","year":"2021","journal-title":"Nat Cancer"},{"key":"2026090203152147200_bib25","doi-asserted-by":"crossref","first-page":"90ra59","DOI":"10.1126\/scitranslmed.3002356","article-title":"Optimization of dosing for EGFR-mutant non\u2013small cell lung cancer with evolutionary cancer modeling","volume":"3","author":"Chmielecki","year":"2011","journal-title":"Sci Transl Med"},{"key":"2026090203152147200_bib26","doi-asserted-by":"crossref","first-page":"38458","DOI":"10.18632\/oncotarget.6276","article-title":"Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer","volume":"6","author":"Sch\u00f6ttle","year":"2015","journal-title":"Oncotarget"},{"key":"2026090203152147200_bib27","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/neuonc\/nor121","article-title":"Pulsatile\u2019 high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer","volume":"13","author":"Grommes","year":"2011","journal-title":"Neuro-oncology"},{"key":"2026090203152147200_bib28","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1097\/JTO.0b013e31826146ee","article-title":"Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer","volume":"7","author":"Foo","year":"2012","journal-title":"J Thorac Oncol"},{"key":"2026090203152147200_bib29","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nmeth.3853","article-title":"Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs","volume":"13","author":"Hafner","year":"2016","journal-title":"Nat Methods"},{"key":"2026090203152147200_bib30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nmeth.3852","article-title":"An unbiased metric of antiproliferative drug effect in vitro","volume":"13","author":"Harris","year":"2016","journal-title":"Nat Methods"},{"key":"2026090203152147200_bib31","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cels.2019.01.003","article-title":"Quantifying drug combination synergy along potency and efficacy axes","volume":"8","author":"Meyer","year":"2019","journal-title":"Cell Syst"},{"key":"2026090203152147200_bib32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/BF02418571","article-title":"Sur les fonctions convexes et les in\u00e9galit\u00e9s entre les valeurs moyennes","volume":"30","author":"Jensen","year":"1906","journal-title":"Acta mathematica"},{"key":"2026090203152147200_bib33","first-page":"299","article-title":"(Anti) fragility and convex responses in medicine","volume-title":"International conference on complex systems","author":"Taleb","year":"2018"},{"key":"2026090203152147200_bib34","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1007\/s11095-022-03380-1","article-title":"Embracing project optimus: can we leverage evolutionary theory to optimize dosing in oncology?","volume":"39","author":"Qi","year":"2022","journal-title":"Pharm Res"},{"key":"2026090203152147200_bib35","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/s41467-017-01968-5","article-title":"Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer","volume":"8","author":"Zhang","year":"2017","journal-title":"Nat Commun"},{"key":"2026090203152147200_bib36","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-19-2669","article-title":"Towards multi-drug adaptive therapy","volume":"80","author":"West","year":"2020","journal-title":"Cancer Res"},{"key":"2026090203152147200_bib37","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1158\/0008-5472.CAN-23-2040","article-title":"Mathematical model-driven deep learning enables personalized adaptive therapy","volume":"84","author":"Gallagher","year":"2024","journal-title":"Cancer Res"},{"key":"2026090203152147200_bib38","doi-asserted-by":"crossref","first-page":"e84263","DOI":"10.7554\/eLife.84263","article-title":"A survey of open questions in adaptive therapy: bridging mathematics and clinical translation","volume":"12","author":"West","year":"2023","journal-title":"Elife"},{"key":"2026090203152147200_bib39","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1158\/0008-5472.CAN-20-0806","article-title":"Turnover modulates the need for a cost of resistance in adaptive TherapyTurnover modulates resistance costs in adaptive therapy","volume":"81","author":"Strobl","year":"2021","journal-title":"Cancer Res"},{"key":"2026090203152147200_bib40","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s41559-021-01428-w","article-title":"A theoretical analysis of tumour containment","volume":"5","author":"Viossat","year":"2021","journal-title":"Nat Ecol Evol"},{"key":"2026090203152147200_bib41","doi-asserted-by":"crossref","first-page":"327ra24","DOI":"10.1126\/scitranslmed.aad7842","article-title":"Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer","volume":"8","author":"Enriquez-Navas","year":"2016","journal-title":"Sci Transl Med"},{"key":"2026090203152147200_bib42","first-page":"p510-525.e6","article-title":"To modulate or to skip: De-escalating PARP inhibitor maintenance therapy in ovarian cancer using adaptive therapy","volume":"15","author":"Strobl","year":"2024","journal-title":"Cell Syst"},{"key":"2026090203152147200_bib43","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ebiom.2019.09.023","article-title":"Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma","volume":"48","author":"Smalley","year":"2019","journal-title":"EBioMedicine"},{"key":"2026090203152147200_bib44","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3390\/e25020343","article-title":"Working with convex responses: antifragility from finance to oncology","volume":"25","author":"Taleb","year":"2023","journal-title":"Entropy"},{"key":"2026090203152147200_bib45","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1007\/s13235-023-00520-z","article-title":"Games and the treatment convexity of cancer","volume":"13","author":"Bayer","year":"2023","journal-title":"Dynamic Games Appl"},{"key":"2026090203152147200_bib46","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11538-024-01278-0","article-title":"Second-order effects of chemotherapy pharmacodynamics and pharmacokinetics on tumor regression and cachexia","volume":"86","author":"Pierik","year":"2024","journal-title":"Bull Math Biol"},{"key":"2026090203152147200_bib47","doi-asserted-by":"crossref","first-page":"100417","DOI":"10.1016\/j.crmeth.2023.100417","article-title":"Phenotypic deconvolution in heterogeneous cancer cell populations using drug-screening data","volume":"3","author":"K\u00f6hn-Luque","year":"2023","journal-title":"Cell Rep Methods"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-25-4262\/3796627\/can-25-4262.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-25-4262\/3805184\/can-25-4262.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/17\/4434\/3823113\/can-25-4262.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/17\/4434\/3823113\/can-25-4262.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:15:33Z","timestamp":1788333333000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/86\/17\/4434\/787505\/Evolutionary-Antifragile-Therapy-Is-a-Treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":47,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,5,21]]},"published-print":{"date-parts":[[2026,9,2]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-25-4262","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.33414969","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414966","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414963","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414972","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.8688036","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]}}}